Abstract CT137: ENLIGHTen-01: a phase 1 study of fluorescein-specific (FITC-E2)-car T cells in combination with folate-fluorescein (UB-TT170) for osteosarcoma
Catherine M. Albert(Seattle Children's Hospital), Julie R. Park(Seattle Children's Hospital), Ashley Wilson(Center for Infectious Disease Research), Jacob Garcia(Unknown), Jeffrey Teoh, Stephanie Rawlings-Rhea(Seattle Children's Hospital), Wenjun Huang(Chengdu Research Base of Giant Panda Breeding), Prabha Narayanaswamy, Rebecca Gardner(Seattle Children's Hospital), Stephanie Mgebroff(Bloodworks Northwest), Navin Pinto(Seattle Children's Hospital), Kristy Seidel(Fred Hutch Cancer Center), Mallory Taylor(Center for Cancer and Blood Disorders), Michael C. Jensen(Seattle Children's Hospital), Christopher Brown, Rimas J. Orentas(Capital Caring)
Cited by 1
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754